Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert

Sponsor
Medical University of Graz (Other)
Overall Status
Unknown status
CT.gov ID
NCT01720394
Collaborator
Medical University of Vienna (Other), Medical University Innsbruck (Other), Klinikum Klagenfurt am Wörthersee (Other), University of Salzburg (Other), Hospital Hartberg, Austria (Other), Hospital Braunau, Austria (Other)
253
7
2
73
36.1
0.5

Study Details

Study Description

Brief Summary

The purpose of the study is to determine the efficacy of a silicone-double-balloon-catheter for cervical ripening and labor induction in women with unfavorable cervix (Bishop Score not greater than 6) compared to medical treatment using a dinoprostone slow-release-vaginal-insert.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
253 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert - a Multicenter Randomized Controlled Trial
Study Start Date :
Nov 1, 2013
Anticipated Primary Completion Date :
Jul 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cervical ripening balloon

primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.

Device: Cervical Ripening Balloon, Cook Medical Inc.
Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
Other Names:
  • Cook cervical ripening balloon, Cook OB/GYN, Spencer, IN, 47460 USA - CE 0088, 400470E
  • Propess-vaginal-insert (Dinoprostone 10mg), Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria
  • Active Comparator: Propess

    Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)

    Drug: Dinoprostone
    Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
    Other Names:
  • Propess, (Dinoprostone 10mg), Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria
  • Outcome Measures

    Primary Outcome Measures

    1. time interval from primary treatment to delivery [maximum of 72 hours]

      the time interval between the first application of the cervical ripening balloon (therapy arm 1) to delivery and the time between first application of dinoprostone vaginal-insert (therapy arm 2) to delivery is measured

    Secondary Outcome Measures

    1. progress of labor [maximum of 72 hours]

      time from balloon-application to dilatation of the cervix (cervical opening > 3cm, or Bishop Score ≥ 9 ) in therapy arm 1 and from dinoprostone-vaginal-insert-application to dilatation of the cervix (cervical opening > 3cm, or Bishop Score ≥ 9 ) in therapy arm 2

    2. vaginal delivery [maximum of 72 hours]

      Number of patients who achieve spontaneous vaginal delivery or vaginal-operative delivery in therapy arm 1 and 2.

    3. failed induction of labor [maximum of 72 hours]

      Number of patients who received caesarean section after frustrating induction of labor. Frustrating induction is defined as application of the cervical-ripening-balloon + 2 times application of dinoprostone-vaginal-insert in therapy arm 1 and 3 times application of dinoprostone-vaginal-insert in therapy arm 2.

    4. patient's satisfaction [participants will be followed for the duration of hospital stay, an expected average of 5-7 days]

      Patient's satisfaction with treatment is evaluated with a questionnaire within 48 h after delivery

    5. maternal parameters [primary treatment - 48h postpartal, leading to a maximum time frame of 5 days]

      signs of infection (temperature, CRP, WBC), childbirth--related injuries,need for epidural in therapy arm 1 and 2.

    6. fetal parameters [primary treatment - fetal hospital discharge, with an expected maximum of 3 months]

      umbilical cord blood values, apgar score, fetal birth weight,number of admissions to ICU and days at ICU in therapy arm 1 and 2.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • medical indication for induction of labor

    • 18 years of age

    • signed informed consent

    • cephalic presentation

    • no PROM

    • 37+0 - 42+0 weeks of gestation

    • Bishop-Score ≤ 6

    • no contra-indication for medical induction of labor

    • no clinical signs of infection

    Exclusion Criteria:
    • fetal anomalies

    • contra-indications for medical induction of labor

    • placental pathologies

    • St.p. surgery with opening the uterine cavity (incl. caesarean section)

    • PROM

    • multiple gestations

    • < 37-0 weeks of gestation

    • St.p. cervical tear

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Abteilung für Gynäkologie und Geburtshilfe, Krankenhaus St. Josef Braunau Braunau Austria A-5280
    2 Universitätsklinik für Frauenheilkunde und Geburtshilfe, Medizinische Universität Graz Graz Austria A-8036
    3 Abteilung für Gynäkologie und Geburtshilfe, LKH Hartberg Hartberg Austria A-8230
    4 Universitätsfrauenklinik Innsbruck, Medizinische Universität Innsbruck Innsbruck Austria A-6020
    5 Abteilung für Gynäkologie und Geburtshilfe, Perinatalzentrum, Klinikum Klagenfurt am Wörthersee Klagenfurt Austria A-9020
    6 Universitätsklinik für Frauenheilkunde und Geburtshilfe, Landeskrankenhaus Salzburg - Universitätsklinikum der Paracelsus Medizinischen Privatuniversität Salzburg Austria A-5020
    7 Universitätsfrauenklinik Wien, Abteilung für Geburtshilfe und fetomaternale Medizin, Medizinische Universität Wien Vienna Austria A-1090

    Sponsors and Collaborators

    • Medical University of Graz
    • Medical University of Vienna
    • Medical University Innsbruck
    • Klinikum Klagenfurt am Wörthersee
    • University of Salzburg
    • Hospital Hartberg, Austria
    • Hospital Braunau, Austria

    Investigators

    • Study Chair: Philipp Klaritsch, MD, Medical University of Graz
    • Principal Investigator: Philipp Reif, MD, Medical University of Graz

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Medical University of Graz
    ClinicalTrials.gov Identifier:
    NCT01720394
    Other Study ID Numbers:
    • MUG-CRB-2012
    First Posted:
    Nov 2, 2012
    Last Update Posted:
    Sep 11, 2018
    Last Verified:
    Sep 1, 2018
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 11, 2018